MDV Medivation

SAN FRANCISCO, Jan. 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results of its Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives in Salzburg, Austria. This marks the first scientific meeting at which data from the trial will be presented. Topline results from this study were reported in September 2006. The oral presentation (abstract #1662), Dimebon Improves Cognition, Function and Behavior in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomized Clinical Trial, will be given by Rachelle S. Doody, M.D., Ph.D., on Sunday, March 18 at 5:15 p.m. local time. Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease Center, Baylor College of Medicine in Houston. The six-month, randomized, double-blinded, placebo-controlled Phase 2 trial evaluated 183 patients with mild to moderate Alzheimer's disease. Primary and secondary endpoints assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior, and included the same endpoints accepted by the U.S. Food and Drug Administration to approve currently marketed drugs to treat mild to moderate Alzheimer's disease. Dimebon met all five efficacy endpoints in this study with strong statistical significance compared with placebo. Dimebon-treated patients also showed statistically significant improvement over baseline on all five efficacy endpoints, meaning that patients taking Dimebon were at higher levels of performance on all five endpoints at the end of six months than they were before starting the study. About Dimebon Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases. In Alzheimer's disease, Medivation has extended the duration of its Phase 2 efficacy study and expects to announce 12-month efficacy data next quarter. In Huntington's disease, the Company initiated a Phase 1-2a clinical trial of Dimebon in October 2006 in collaboration with the Huntington Study Group and expects to report efficacy data in the second half of this year. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/ . This press release contains forward-looking statements, including statements regarding anticipated announcement dates for clinical trial results, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006, June 30, 2006, and September 30, 2006, include more information about factors that could affect the Company's financial and operating results. DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer, of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for Medivation, Inc. Web site: http://www.medivation.com/

Copyright